BIMINI Biotech

BIMINI Biotech is an innovative startup developing new cancer drugs. With this they want to specifically inhibit the cell growth of cancer cells, via the growth hormone receptor, in a unique way.

BIMINI Biotech develops innovative cancer drugs by specifically inhibiting cell growth. Their approach is based on a new mechanism, looking at the growth hormone that ultimately ensures cell growth, reproduction and regeneration. This approach elegantly mimics nature by making the cell less sensitive to growth hormone, as seen in Laron syndrome (a specific type of dwarfism). In this syndrome, in which the function of the growth hormone receptors is disturbed, resistance appears to exist against cancer, among other things.

The technology is based on pioneering research by Prof. Ger Strous from the University Medical Center Utrecht. Their resources show hopeful results against cancer in the preclinical phase. BIMINI recently moved to Leiden to continue its preclinical research there and to bring the technology to the clinic.

Want to know more?

Please contact the investment manager.

Thijs van den Munckhof

Investment Manager

(Luris/Universiteit Leiden)